Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Vici, Patrizia, Pizzuti, Laura, Natoli, Clara, Moscetti, Luca, Mentuccia, Lucia, Vaccaro, Angela, Sergi, Domenico, Di Lauro, Luigi, Trenta, Patrizia, Seminara, Patrizia, Santini, Daniele, Iezzi, Laura, Tinari, Nicola, Bertolini, Ilaria, Sini, Valentina, Mottolese, Marcella, Giannarelli, Diana, Giotta, Francesco, Maugeri-Saccà, Marcello, Barba, Maddalena, Marchetti, Paolo, Michelotti, Andrea, Sperduti, Isabella, Gamucci, Teresa
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2014
Onderwerpen:
Clinical Trial
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174332/
https://ncbi.nlm.nih.gov/pubmed/25234842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3133-1
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items